Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221828 · ClinicalTrials.gov registry record · Phase 2
Trial of NanoPac Focal Therapy for Prostate Cancer
A Phase 2 study, sponsored by NanOlogy.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04221828 is a Phase 2 study that was terminated before completion, run by NanOlogy. The registered enrollment target is 1 participants.
The verdict
NCT04221828, a Phase 2 study, was terminated before completion, sponsored by NanOlogy.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
Interventions
- DRUG NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2021-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04221828
The ClinicalTrials.gov registry entry for NCT04221828 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NanOlogy, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension is the first listed.
NCT04221828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04221828 about?
NCT04221828 is a clinical study titled "Trial of NanoPac Focal Therapy for Prostate Cancer". This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
What is the current status of trial NCT04221828?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2020-10-20. Estimated completion is 2021-02-08.
What interventions are being tested in trial NCT04221828?
The interventions under investigation include: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension (DRUG).
Who is sponsoring clinical trial NCT04221828?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.